# Supergene, LLC: Phase 3 study completed, 170 enrolled (Acute Limb Ischemia)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Supergene, LLC |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Thrombolysis With Recombinant Non-immunogenic Staphylokinase vs Surgery in Patients With Acute Limb Ischemia FORAT Trial |
| NCT ID | NCT05372718 |
| Phase | Phase 3 |
| Status | completed |
| Conditions | Acute Limb Ischemia |
| Intervention types | drug, procedure |
| Target enrollment | 170 |
| Site countries | Russia |
| Posted | 2022-05-13 |
| Planned start | 2022-12-26 |
| Event | Completed |
| Event date | 2026-09-30 |
| Last update posted | 2026-10-05 |

## Why this score
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.
- Phase 3: multi-site, larger budget.
- 170 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05372718). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.